Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

311 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma.
Piper E, Brightling C, Niven R, Oh C, Faggioni R, Poon K, She D, Kell C, May RD, Geba GP, Molfino NA. Piper E, et al. Among authors: she d. Eur Respir J. 2013 Feb;41(2):330-8. doi: 10.1183/09031936.00223411. Epub 2012 Jun 27. Eur Respir J. 2013. PMID: 22743678 Free PMC article. Clinical Trial.
Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study.
Brightling CE, Bleecker ER, Panettieri RA Jr, Bafadhel M, She D, Ward CK, Xu X, Birrell C, van der Merwe R. Brightling CE, et al. Among authors: she d. Lancet Respir Med. 2014 Nov;2(11):891-901. doi: 10.1016/S2213-2600(14)70187-0. Epub 2014 Sep 7. Lancet Respir Med. 2014. PMID: 25208464 Free PMC article. Clinical Trial.
Effect of Anti-IL-13 Treatment on Airway Dimensions in Severe Asthma.
Brightling CE, Nordenmark LH, Jain M, Piper E, She D, Braddock M, Colice G, Tornling G. Brightling CE, et al. Among authors: she d. Am J Respir Crit Care Med. 2016 Jul 1;194(1):118-20. doi: 10.1164/rccm.201511-2224LE. Am J Respir Crit Care Med. 2016. PMID: 27367889 Clinical Trial. No abstract available.
A randomized, placebo-controlled, single ascending-dose study to assess the safety, tolerability, pharmacokinetics, and immunogenicity of subcutaneous tralokinumab in Japanese healthy volunteers.
Baverel P, She D, Piper E, Ueda S, Yoshioka T, Faggioni R, Gevorkyan H. Baverel P, et al. Among authors: she d. Drug Metab Pharmacokinet. 2018 Jun;33(3):150-158. doi: 10.1016/j.dmpk.2017.12.001. Epub 2017 Dec 12. Drug Metab Pharmacokinet. 2018. PMID: 29622380 Free article. Clinical Trial.
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.
Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, Lublin FD, Drappa J, Barron G, Madani S, Ratchford JN, She D, Cimbora D, Katz E; N-MOmentum study investigators. Cree BAC, et al. Among authors: she d. Lancet. 2019 Oct 12;394(10206):1352-1363. doi: 10.1016/S0140-6736(19)31817-3. Epub 2019 Sep 5. Lancet. 2019. PMID: 31495497 Clinical Trial.
MEDI6012: Recombinant Human Lecithin Cholesterol Acyltransferase, High-Density Lipoprotein, and Low-Density Lipoprotein Receptor-Mediated Reverse Cholesterol Transport.
George RT, Abuhatzira L, Stoughton SM, Karathanasis SK, She D, Jin C, Buss NAPS, Bakker-Arkema R, Ongstad EL, Koren M, Hirshberg B. George RT, et al. Among authors: she d. J Am Heart Assoc. 2021 Jul 6;10(13):e014572. doi: 10.1161/JAHA.119.014572. Epub 2021 Jun 14. J Am Heart Assoc. 2021. PMID: 34121413 Free PMC article. Clinical Trial.
311 results